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Abstract
Background: Both uremia and hepatitis C infection is associated with increased oxidative stress.
In the present study, we aimed to find out whether hepatitis C infection has any impact on oxidative
stress in hemodialysis subjects.
Methods: Sixteen hepatitis C (+) hemodialysis subjects, 24 hepatitis C negative hemodialysis
subjects and 24 healthy subjects were included. Total antioxidant capacity, total peroxide level and
oxidative stress index were determined in all subjects.
Results: Total antioxidant capacity was significantly higher in controls than hemodialysis subjects
with or without hepatitis C infection (all p < 0.05/3), while total peroxide level and oxidative stress
index were significantly lower (all p < 0.05/3). Hepatitis C (-) hemodialysis subjects had higher total
antioxidant capacity compared to hepatitis C (+) hemodialysis subjects (all p < 0.05/3). Total
peroxide level and oxidative stress index was comparable between hemodialysis subjects with or
without hepatitis C infection (p > 0.05/3).
Conclusion: Oxidative stress is increased in both hepatitis C (+) and hepatitis C (-) hemodialysis
subjects. However, hepatitis C infection seems to not cause any additional increase in oxidative
stress in hemodialysis subjects and it may be partly due to protective effect of dialysis treatment
on hepatitis C infection.
Background
Oxidative stress can be defined as an increase in oxidants
and/or a decrease in antioxidant capacity [1], and is being
increasingly associated with a wide spectrum of renal dis-
eases [2,3]. Oxidative stress in chronic renal failure (CRF)
leads to the oxidation of proteins [4], lipids and carbohy-
drates [5], and facilitates the formation of advanced glyca-
tion and lipoxidation products, and possibly promotes
many uremic complications [6,7]. There is good evidence
indicating that uremia, in general, is associated with
enhanced oxidative stress [8,9], and treatment of uremia
with hemodialysis (HD) or peritoneal dialysis (PD) has
been suggested to contribute to oxidative stress and
reduced antioxidant levels in these patients [10,11].
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Several prevalence studies of hepatitis C virus (HCV)
infection have been undertaken in HD patients. The prev-
alence of anti-HCV antibody in HD subjects ranged
between 10% and 55% [12]. The natural course of HCV
infection in HD patients seems to differ from that in other
HCV infected patients. HCV-related liver disease usually
runs an indolent course in HD patients [13]. It has been
shown that HCV infection itself is also characterized by an
increase in free radical formation manifested by increased
hepatic and serum levels of products of lipid peroxidation
[14,15].
Although aggravated production of toxic oxygen radicals
and related compounds has been noted in both HD sub-
jects and subjects with HCV infection, little is known
about the oxidative status in HD subjects with HCV infec-
tion [16-18] and it needs to be elucidated further.
In the present study, we evaluated the oxidative status in
HCV (+) HD subjects, HCV (-) HD subjects and healthy
controls via measurement of total antioxidant capacity
(TAC) [19] and total peroxide level in plasma samples,
and calculation of oxidative stress index (OSI) [20]. Thus,
we aimed to find out whether HCV infection has any
impact on oxidative stress in HD subjects.
Methods
Subjects
Sixteen HCV (+) HD subjects, 24 HCV (-) HD subjects and
24 healthy controls were enrolled in the present cross-sec-
tional study. All HD subjects consisted of patients with
end-stage renal disease (ESRD) (creatinine clearance = 5
ml/min/1.73m2BS), who underwent HD treatment thrice
weekly for 4 hours/day with blood flow rates of 180–200
ml/min and dialysate flow rates of 480–500 ml/min using
bicarbonate dialysate on hollow-fiber artificial kidneys.
Most HD patients were receiving antihypertensive medi-
cations (beta blocker, calcium channel blockers, angi-
otensin-converting enzyme inhibitors and angiotensin-II
type 1 receptor blocker). The patients were selected on the
basis of their stable clinical condition over the past 3
months. The study protocol was carried out in accordance
with the Helsinki Declaration as revised in 1989. All sub-
jects were informed about the study and the written con-
sent was obtained from each one.
The etiology of ESRD in group 1 and 2 was as follows:
Group 1; interstitial nephritis (n = 4), hypertensive neph-
rosclerosis (n = 6), chronic glomerulonephritis (n = 3),
and shrunken kidney with unknown etiology (n = 3).
Group 2; interstitial nephritis (n = 7), hypertensive neph-
rosclerosis (n = 4), chronic glomerulonephritis (n = 5),
polycystic disease (n = 3), and shrunken kidney with
unknown etiology (n = 5).
HCV infection was diagnosed by the positivity of anti-
HCV and HCV-RNA for at least 6 months of period. In
order to avoid the possibility of false negative results,
HCV-RNA detection was performed in the whole HD pop-
ulation including HCV negative HD patients.
Exclusion criteria
History of alcohol abuse, smoking habit, intravenous (IV)
drug abuse, pregnancy, and antioxidant use, fish-oil or
iron supplement in the previous month, receiving antivi-
ral and/or interferon therapy for HCV (+) subjects, uncon-
trolled elevated blood pressure, serum total bilirubin level
higher than 2 mg/dL, concomitant chronic hepatitis B or
other well known liver diseases such as metabolic or
autoimmune disorders and various infectious states of the
liver, cryglobulinemia, human immune deficiency virus
(HIV) infection, diabetes mellitus, chronic respiratory
insufficiency, rheumatoid arthritis, cirrhosis, or malignant
tumor.
Virological studies
Anti-HCV was assayed by micro particle enzyme immu-
noassay (MEIA) (Abbott axsym system, IL USA). HCV-
RNA was determined using real time polymerase chain
reaction (RT-PCR) method [(Fluorion HCV QNP 2.1
HCV-RNA quantitative kits, Iontek, Istanbul, Turkey)
(BioRad ICycler)]. Upper and lower limit of HCV-RNA
levels with RT-PCR were 102 and 107 copy/ml, respec-
tively.
Blood collection
Blood samples were obtained in fasting state. Blood sam-
ples from dialysis patients were drawn immediately
before HD session. Samples were withdrawn from a
cubital vein into heparinised tubes and immediately
stored on ice at 4°C. The plasma was then separated from
the cells by centrifugation at 900 × g for 10 min, and the
plasma samples were stored at -80°C until analysis as
described elsewhere [19,21].
Biochemical analysis
Serum uric acid, creatinine and blood urea nitrogen
(BUN) level were determined using auto-analyzer.
Measurement of the total antioxidant status of plasma
The total antioxidant status of the plasma was measured
using a novel automated colorimetric measurement
method for TAC developed by Erel [19]. In this method
the hydroxyl radical, the most potent biological radical, is
produced by the Fenton reaction, and reacts with the
colorless substrate O-dianisidine to produce the dianisyl
radical, which is bright yellowish-brown in color. UponBMC Infectious Diseases 2006, 6:114 http://www.biomedcentral.com/1471-2334/6/114
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the addition of a plasma sample, the oxidative reactions
initiated by the hydroxyl radicals present in the reaction
mix are suppressed by the antioxidant components of the
plasma, preventing the color change and thereby provid-
ing an effective measure of the total antioxidant capacity
of the plasma. The assay results are expressed as mmol
Trolox eq./L. Within- and between-batch precision values
were lower than 3% [19,22].
Measurement of total plasma peroxide concentration
The total plasma peroxide concentrations were deter-
mined using the ferrous oxidation in xylenol orange
(FOX)-2 method [23] with minor modifications [20]. The
FOX-2 test system is based on the oxidation of ferrous iron
to ferric iron by the various types of peroxides contained
in the plasma samples, in the presence of xylenol orange
which produces a colored ferric-xylenol orange complex
whose absorbance can be measured. The FOX2 reagent
was prepared by dissolving ammonium ferrous sulphate
(9.8 mg) in 250 mM H2SO4 (10 ml) to give a final concen-
tration of 250 mM ferrous iron in acid. This solution was
then added to 90 ml HPLC-grade methanol containing
79.2 mg butylated hydroxytoluene (BHT). Finally, 7.6 mg
xylenol orange was added, with stirring, to make the
working reagent (250 mM ammonium ferrous sulphate,
100 mMxylenol orange, 25 mM H2SO4, and 4 nM BHT, in
90% (v/v) methanol in a final volume of 100 ml). The
blank reagent contained all the components of the solu-
tion except ferrous sulphate. Aliquots (200 μL) of plasma
were mixed with 1.8 ml FOX2 reagent. After incubation at
room temperature for 30 min, the vials were centrifuged
at 12,000 g for 10 min. The absorbance of the supernatant
was then determined at 560 nm. The total peroxide con-
tent of the plasma samples was determined as a function
of the difference in absorbance between the test and blank
samples using a solution of H2O2 as standard. The coeffi-
cient of variation for individual plasma samples was less
than 5%.
Oxidative stress index
The ratio percentage of the total peroxide to the total anti-
oxidant potential gave the oxidative stress index, an indi-
cator of the degree of oxidative stress [20].
Statistical analysis
Data were presented as mean ± SD. Qualitative variables
were assessed by Chi-square test. Non-parametric contin-
uous variables were compared by the Kruskal-Wallis one-
way analysis of variance with posthoc analysis using a
Mann-Whitney U test. Parametric variables were com-
pared using Student t test and one-way analysis of vari-
ance with post-hoc analysis using the Tukey test. Pearson's
correlation analysis was used to find out the relationship
of alanine aminotransferase with HCV-RNA level in HCV
(+) HD subjects. Multiple linear regression analysis was
used to find out the relationship of age, gender, dialysis
duration, HCV positivity, uric acid, BUN and creatinine
with oxidative stress markers. Differences were regarded as
significant at 0.05/3 for comparisons were made by
Kruskal-Wallis one-way analysis of variance, otherwise at
p < 0.05.
Results
The demographic, clinical and laboratory data of the
groups are shown in Table 1. There were no statistically
significant differences between the groups with respect to
age and gender (both p > 0.05). Dialysis duration was
comparable between HD subjects with or without HCV
infection (P > 0.05). Serum uric acid, BUN and creatinine
levels were significantly higher in HD subjects with or
without HCV infection than controls (all p < 0.05). There
was no statistically significant difference between HD sub-
jects with or without HCV infection in respect to serum
creatinine, urea and uric acid level (all p > 0.05). ALT lev-
els were comparable between HD subjects with and with-
out HCV infection and controls (all p > 0.05). No
correlation was observed between ALT and HCV-RNA
level in HCV (+) HD subjects (p > 0.05).
TAC was significantly higher in controls than HD subjects
with or without HCV infection (all p < 0.05/3), while total
peroxide level and OSI were significantly lower (all p <
0.05/3). HCV (-) HD subjects had higher TAC compared
to HCV (+) HD subjects (all p < 0.05/3). Total peroxide
level and OSI was comparable between HD subjects with
or without HCV infection (p > 0.05/3) (Figure 1, 2, 3).
In multiple linear regression analysis, TAC, total peroxide
level or OSI were not correlated with age, gender, dialysis
duration, HCV positivity, and serum uric acid, BUN and
creatinine level (all p > 0.05).
Discussion
Increased oxidative damage due to reactive oxygen species
has been reported in HD subjects [8,9]. Several potential
sources such as increase in neutrophil free radical produc-
tion during HD [24], iron overload [25], reduction of
antioxidant enzyme activity due to advanced glycation
end products (AGEP)-induced posttranslational modifi-
cation [26] have been suggested to be responsible from
increased radical production in CRF. The increase in free
radical formation, manifested by increased hepatic and
serum levels of lipid peroxidation products [14,15], and
decreased antioxidant levels [27] have also been reported
in subjects with HCV infection.
In the previous studies, which were conducted in HCV (+)
HD subjects, the oxidative status of subjects was deter-
mined using measurement of pentosidine level [17],
thioredoxin level [18] or both malondialdehyde (MDA),BMC Infectious Diseases 2006, 6:114 http://www.biomedcentral.com/1471-2334/6/114
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protein carbonyl content and protein sulfhydryl groups
[16]. It is well known that, the effects of various antioxi-
dants in plasma are additive and the cooperation of anti-
oxidants in human serum provides protection of the
organism against attacks by free radicals [28]. Therefore,
the measurement of TAC may reflect accurately the anti-
oxidant status of the organism [1,19]. Although determi-
nation of either oxidants or antioxidant components
alone may give information about the oxidative stress,
determination of oxidants along with antioxidants is
more useful in this context. Therefore, oxidants and anti-
oxidant capacity should be measured simultaneously to
assess oxidative stress more exactly. In addition, the ratio
percentage of the total plasma peroxide level to TAC,
regarded as OSI, an indicator of oxidative stress, reflects
the redox balance between oxidation and antioxidation
[19,20]. Although, in those previous studies [16-18], HCV
(+) HD subjects have been reported to be under higher
oxidative stress compared to HCV (-) HD subjects, TAC
was not determined and OSI was not calculated. Thus, this
is the first study determining oxidative status of HD sub-
jects with or without HCV infection using measurement
of TAC along with measurement of total peroxide level
and calculation of OSI.
In the present study, if only total antioxidant capacity
measurement results were taken into account, HCV (+)
HD subjects might be falsely assumed to have aggravated
oxidative stress compared to HCV (-) HD subjects. How-
ever, total peroxide level and OSI, which reflects the redox
balance between oxidation and antioxidation, showed no
difference between those groups. On the basis of these
findings, it can be suggested that HCV infection has no
additional influence on oxidative status in HD subjects.
Both HD subjects with or without HCV infection had higher  oxidative stress index than controls Figure 3
Both HD subjects with or without HCV infection had higher 
oxidative stress index than controls. However, oxidative 
stress index was comparable between HD subjects with or 
without HCV infection. HCV, hepatitis C; HD, hemodialysis. 
*p < 0.05/3 vs. controls.
HCV (+) HD subjects had lower TAC than HCV (-) HD sub- jects Figure 1
HCV (+) HD subjects had lower TAC than HCV (-) HD sub-
jects. Both HD subjects with or without HCV infection had 
also lower TAC than controls. TAC, total antioxidant capac-
ity; HCV, hepatitis C; HD, hemodialysis. *p < 0.05/3 vs. HC 
(+) HD subjects. **p < 0.05/3 vs. HD subjects with or with-
out HCV infection.
Both HD subjects with or without HCV infection had higher  total peroxide level than controls Figure 2
Both HD subjects with or without HCV infection had higher 
total peroxide level than controls. However, total peroxide 
level was comparable between HD subjects with or without 
HCV infection. HCV, hepatitis C; HD, hemodialysis. *p < 
0.05/3 vs. controls.BMC Infectious Diseases 2006, 6:114 http://www.biomedcentral.com/1471-2334/6/114
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Since each one of ESRD and HCV infection increases oxi-
dative stress, it is logical to expect that HCV (+) HD sub-
jects may be under higher oxidative stress than HCV (-)
HD subjects. It has been shown that HCV viral load in HD
population with HCV infection is typically low and sug-
gested that the HD procedure lowers HCV RNA levels by
various mechanisms: the clearance of HCV RNA by the
dialysate, the entrapment of HCV RNA particles onto the
membrane surface of dialyser, and the production of
cytokines and other substance during the HD session [29].
Although, in HD subjects, HCV-related liver disease usu-
ally runs an indolent course [13], the mortality of HCV
infected HD patients seems to be enhanced compared
with HCV (-) HD patients and it is mainly due to hepato-
cellular carcinoma and liver cirrhosis [30,31]. It has been
suggested that increased oxidative stress is a possible risk
factor contributing to development of DNA damage,
which may be associated with various cancers and cardio-
vascular disease [32]. However, in accordance with our
observation, there is no data reflecting additional increase
in oxidative stress, and consequently in DNA damage
among HCV (+) HD subjects. Although the incidence of
liver cancer among HCV (+) HD subjects has been
reported to be significantly higher than HCV (-) HD sub-
jects [33], it seems equal to the reported incidence of liver
cancer among HCV (+) subjects without renal disease [34-
36]. In addition, there is no data reporting increased inci-
dence of the other disorders such as other cancers, cardio-
vascular and neurodegenerative diseases, which might be
associated with increased oxidative stress, and conse-
quently in DNA damage among HCV (+) HD subjects
compared to HCV (-) HD subjects.
In the present study, in respect to ALT levels, no significant
difference was observed between HD subjects with or
without HCV infection and controls. It has been reported
that ALT levels in anti-HCV positive subjects on mainte-
nance dialysis are often in range considered normal for
the general population [37]. In this regard; our finding
was consistent with the literature. Although the precise
role of viral, host and/or environmental factors in pro-
moting disease progression have yet to be defined in dial-
ysis subjects, it has been reported that inflammatory
cytokine responses such as production of tumor necrosis
factor (TNF)-alpha, interleukin (IL-) 6, IL-10, interferon
(IFN-) gamma by blood mononuclear cells were abol-
ished in hemodialysis patients. The pattern of response
reported to be similar among hemodialysis patients with
or without HCV infection. In addition, it has been shown
that HCV-positive hemodialysis patients had a blunted
TNF-alpha response and failed to increase the stimulated
IFN-gamma and IL-12 production compared with chronic
hepatitis C patients without renal disease [38]. Therefore,
both the protective activity of hemodialysis on the course
of HCV infection and attenuated inflammatory reactions
in the liver due to reduced immune competence of
chronic uremic patients may be plausible factors reducing
hepatocyte destruction, which reflected by the ALT levels.
Our study has several shortcomings that need to be
stressed. Firstly, the oxidative stress assessment was based
Table 1: Clinical and demographic characteristics of the study groups.
Study Groups HCV (+) HD subjects HCV (-) HD subjects Control subjects
N 16 24 24
Age (year) 50.3 ± 10 46.8 ± 8.5 40.4 ± 7.3
Gender (M/F) 10/6 13/11 14/10
Uric Acid (mg/dL) 5.5 ± 1.5* 5.54 ± 1.25* 4.4 ± 0.3
BUN (mg/dL) 61 ± 23* 65 ± 31* 16 ± 5.5
ALT 27 ± 13.7 22.4 ± 10.7 23.3 ± 4.8
Creatinine (mg/dL) 6.05 ± 2.4* 7.01 ± 1.5* 0.97 ± 0.15
HCV-RNA (log copies/mL) 4.9 ± 0.7 -- --
DD (Years) 4.25 ± 2.5 3.35 ± 2.7 --
TAC ( mmol Trolox eq./L) 1.27 ± 0.2 1.68 ± 0.4 2.1 ± 0.6**
TP (micromole H2O2/L) 12.9 ± 6.1** 10.9 ± 6.9** 5.2 ± 2.1
OSI (%) 1.6 ± 0.6** 1.1 ± 0.9** 0.3 ± 0.1
Data were presented as mean ± SD.
*p < 0.05 vs. controls.
**p < 0.05/3 vs. HD subjects with or without HCV infection.
***p < 0.05/3 vs. controls.
M, male; F, female; DD, dialysis duration; BUN, blood urea nitrogen; HD, hemodialysis;
HCV, hepatitis C virus; ALT, alanine aminotransferase; TAC, total antioxidant capacity; TP, total peroxide level; OSI, oxidative stress index.BMC Infectious Diseases 2006, 6:114 http://www.biomedcentral.com/1471-2334/6/114
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on single determination of plasma peroxide concentra-
tion. A sequential measurement could be necessary to
avoid possible plasma fluctuations of peroxide concen-
tartion Secondly, only one oxidative stress marker was
used to portrait oxidative status. Other oxidative stress
markers which are recognizably elevated in HD popula-
tion such as markers of protein, lipids and DNA damage
were not measured. Finally, inflammatory markers which
are well known as strong predictor of mortality were not
provided.
In conclusion, in the lightening of our findings, it can be
suggested that oxidative stress is increased in both HCV
(+) and HCV (-) HD subjects. However, HCV infection
seems to not cause any additional increase in oxidative
stress in HD subjects and it may be partly due to protective
effect of dialysis treatment on HCV infection.
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